Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.12), Zacks reports.
Chemomab Therapeutics Stock Performance
Shares of NASDAQ CMMB opened at $2.07 on Friday. The firm has a 50 day moving average price of $1.72 and a two-hundred day moving average price of $1.71. The stock has a market cap of $14.90 million, a P/E ratio of -0.97 and a beta of 0.65. Chemomab Therapeutics has a 52-week low of $1.35 and a 52-week high of $4.12.
Wall Street Analyst Weigh In
Separately, Weiss Ratings raised Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $25.00.
Institutional Trading of Chemomab Therapeutics
A hedge fund recently bought a new stake in Chemomab Therapeutics stock. XTX Topco Ltd acquired a new stake in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,013 shares of the company’s stock, valued at approximately $31,000. XTX Topco Ltd owned 0.31% of Chemomab Therapeutics as of its most recent SEC filing. Institutional investors own 46.05% of the company’s stock.
About Chemomab Therapeutics
Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.
Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.
Further Reading
- Five stocks we like better than Chemomab Therapeutics
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
